In-silico drug design of some bioactive compounds against BRCA1 for treatment of cancer
Authors/Creators
-
1.
Gopalganj Science and Technology University
Description
Abstract: Breast cancer susceptibility gene 1 (BRCA1) is a pivotal tumor suppressor gene involved in DNA repair, transcriptional regulation, and cell cycle control. Mutations or dysregulation of BRCA1 are strongly associated with breast and ovarian cancers. This study employs in silico drug design techniques to identify potential bioactive compounds targeting BRCA1, aiming to restore or enhance its functionality and thereby combat cancer progression. A library of bioactive compounds was screened using molecular docking and virtual screening to identify high-affinity binders to key functional domains of BRCA1, particularly its RING and BRCT domains. Computational techniques such as molecular dynamics simulations, ADMET predictions (absorption, distribution, metabolism, excretion, and toxicity), and pharmacophore modeling were employed to optimize the lead compounds for efficacy and safety. Several candidate compounds demonstrated promising binding affinities, with favorable interaction profiles and stable conformations within BRCA1 active sites. ADMET analysis highlighted drug-like properties, supporting their potential for further development. In silico identifies bioactive compounds with a potential for BRCA1 modulation, opening doors for BRCA1-related therapies with a target basis for future development. In future studies, high priority will be placed in in vitro and in vivo experiments confirming such compounds for testing them for therapeutic use. In drug discovery, such a role is critical in defining efficacy and toxicity of compounds prior to proceeding with clinical trials.
Key words: Bioactive compounds, BRCA1, in silico drug design, molecular docking, visualization, DFT, ADMET analysis.
Files
In-silico drug design of some bioactive compounds against BRCA1 for treatment of cancer.pdf
Files
(1.1 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:1a9932cf5c18c31837e051801b1de04f
|
1.1 MB | Preview Download |
Additional details
Software
- Repository URL
- https://www.ijisdd.com/
References
- 1. Savage, K.I. and D.P. Harkin, BRCA 1, a 'complex'protein involved in the maintenance of genomic stability. The FEBS journal, 2015. 282(4): p. 630-646. 2. Chatterjee, N. and G.C. Walker, Mechanisms of DNA damage, repair, and mutagenesis. Environmental and molecular mutagenesis, 2017. 58(5): p. 235-263. 3. Trott, O. and A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 2010. 31(2): p. 455-461. 4. Jorgensen, W.L., The many roles of computation in drug discovery. Science, 2004. 303(5665): p. 1813-1818. 5. Kitchen, D.B., et al., Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery, 2004. 3(11): p. 935-949. 6. Lagunin, A., et al., PASS: prediction of activity spectra for biologically active substances. Bioinformatics, 2000. 16(8): p. 747-748. 7. Goel, R.K., et al., PASS-assisted exploration of new therapeutic potential of natural products. Medicinal Chemistry Research, 2011. 20: p. 1509-1514. 8. Sadym, A., et al., Prediction of biological activity spectra via the Internet. SAR and QSAR in Environmental Research, 2003. 14(5-6): p. 339-347. 9. Coordinators, N.R., Database resources of the national center for biotechnology information. Nucleic acids research, 2013. 41(Database issue): p. D8. 10. Guex, N. and M.C. Peitsch, SWISS‐MODEL and the Swiss‐Pdb Viewer: an environment for comparative protein modeling. electrophoresis, 1997. 18(15): p. 2714-2723. 11. de Oliveira, P.D., et al., Investigation of antibacterial mode of action of ω-aminoalkoxylxanthones by NMR-based metabolomics and molecular docking. Metabolomics, 2025. 21(1): p. 1-11. 12. Bank, W.P.D., Protein Data Bank (PDB)[Database]. 13. DeLano, W., The PyMOL Molecular Graphics System. DeLano Scientific, 2002. 14. Kawsar, S.M., et al., In silico pharmacokinetics, molecular docking and molecular dynamics simulation studies of nucleoside analogs for drug discovery-a mini review. Mini Reviews in Medicinal Chemistry, 2024. 24(11): p. 1070-1088. 15. Roche, D.B., D.A. Brackenridge, and L.J. McGuffin, Proteins and their interacting partners: An introduction to protein–ligand binding site prediction methods. International journal of molecular sciences, 2015. 16(12): p. 29829-29842. 16. Studio, D., Discovery studio. Accelrys [2.1], 2008. 420. 17. Jones, G., et al., Development and validation of a genetic algorithm for flexible docking. Journal of molecular biology, 1997. 267(3): p. 727-748. 18. Morris, G.M., et al., AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry, 2009. 30(16): p. 2785-2791. 19. Halgren, T., New method for fast and accurate binding‐site identification and analysis. Chemical biology & drug design, 2007. 69(2): p. 146-148. 20. Sánchez-Martínez, C., et al., Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019). Bioorganic & medicinal chemistry letters, 2019. 29(20): p. 126637. 21. Moussaoui, M., et al., In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies. Journal of Biomolecular Structure and Dynamics, 2023. 41(23): p. 13646-13662. 22. Abookleesh, F., et al., Assessing Molecular Docking Tools to Guide the Design of Polymeric Materials Formulations: A Case Study of Canola and Soybean Protein. Polymers, 2022. 14(17): p. 3690. 23. Rehman, M.U., et al., In Silico molecular docking and dynamic analysis of natural compounds against major non-structural proteins of SARS-COV-2. Journal of Biomolecular Structure and Dynamics, 2023. 41(18): p. 9072-9088. 24. Zainulabidin, A.A., A.J. Sufyan, and M.K. Thirunavukkarasu, Triple-Action Therapy: Combining Machine Learning, Docking, and Dynamics to Combat BRCA1-Mutated Breast Cancer. Molecular Biotechnology, 2024: p. 1-16. 25. Issahaku, A.R. and M.E. Soliman, Investigating the impact of covalent and non-covalent binding modes of inhibitors on Bruton's tyrosine kinase in the treatment of B cell malignancies-computational insights. Current Pharmaceutical Biotechnology, 2023. 24(6): p. 814-824. 26. Frisch, A., gaussian 09W Reference. Wallingford, USA, 25p, 2009. 470. 27. Liu, Z.-K., Computational thermodynamics and its applications. Acta Materialia, 2020. 200: p. 745-792. 28. Mayanglambam, R.S., et al., Anticorrosive Activity of Melothria Perpusilla: A Renewable and Sustainable Inhibitor. Available at SSRN 4730136. 29. Namitha, R. and E. Vidya, DFT Investigation of Corrosion Inhibition and Nonlinear Optical Behaviour of Phenylimidazolidin-4-One Derivative. International journal of advanced Science and Engineering, 2021. 8(2): p. 2153. 30. Nisha, C.M., et al., Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor. Journal of Molecular Graphics and modelling, 2016. 65: p. 100-107. 31. Lambrinidis, G., T. Vallianatou, and A. Tsantili-Kakoulidou, In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review. Advanced drug delivery reviews, 2015. 86: p. 27-45. 32. Khalipha, A.B.R., et al., A Literature Based Review on Rohitukine and Molecular Docking Studies of Flavopiridol (Rohitukine Derived) and Its Derivatives against Cyclin-Dependent Kinases (CDKs) for Anticancer Activity. Int. J. Sci. Res, 2019. 1: p. 15-28. 33. Pardridge, W.M., The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2005. 2: p. 3-14. 34. Wessel, M.D., et al., Prediction of human intestinal absorption of drug compounds from molecular structure. Journal of Chemical Information and Computer Sciences, 1998. 38(4): p. 726-735. 35. Choi, I., et al., Classification models for CYP450 3A4 inhibitors and non-inhibitors. European journal of medicinal chemistry, 2009. 44(6): p. 2354-2360. 36. B Fernandes, T., et al., Analysis of the applicability and use of lipinskis rule for central nervous system drugs. Letters in Drug Design & Discovery, 2016. 13(10): p. 999-1006.